Angiogenesis inhibitors
AssigneeCarlsbad Technology, Inc.
InventorsChe-Ming Teng, Sheng-Chu Kuo, Fang Yu Lee, Shiow-Lin Pan, Jih-Hwa Guh
Life of this patent
Estimating the term…
Abstract
A method for treating an angiogenesis-related disorder. The method includes administrating to a subject in need thereof an effective amount of a compound of the formula: Each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, furyl, pyrrolyl, pyridinyl, or pyrimidinyl; each of R1, R2, R3, R4, R5, and R6, independently, is R, nitro, halogen, C(O)OR, C(O)SR, C(O)NRR′, (CH2)mOR, (CH2)mSR, (CH2)mNRR′, (CH2)mCN, (CH2)mC(O)OR, (CH2)mCHO, (CH2)mCH═NOR, or R1 and R2 together, R3 and R4 together, or R5 and R6 together are O(CH2)mO, in which each of R and R′, independently, is H or C1˜C6 alkyl; and m is 0, 1, 2, 3, 4, 5, or 6, and n is 0, 1, 2, or 3.
Claims7
A method for inhibiting endothelial cell proliferation, comprising administering to a subject in need thereof an effective amount of a compound of the formula:
- Wherein
- each of Ar1, and Ar3 is phenyl;
- Ar2 is furyl or phenyl;
- one of R1, and R2 is H, and the other is C1–C6 alkyl or halogen;
- one of R3, and R4 is H, and the other is CH2OH;
- each of R5, and R6 is H;
- n is 1;
- and
- said endothelial cell proliferation is responsible for treating an angiogenesis-related disorder.
Dependencies are inferred from the claim text.